It is estimated that 90% of all breast cancers are detected at an early stage. Although the prognosis for  is generally positive, 20% of patients will experience recurrence potentially to incurable metastatic disease. [1]

The risk of recurrence is greatest within the initial two to three years post-diagnosis, particularly in patients with node-positive, high risk early breast cancer.a [2]

Factors associated with high risk of recurrence generally include a positive nodal status, large tumor size (≥5 cm), a high tumor grade (Grade 3), and high rate of cellular proliferation [Ki-67 score (≥20%)].

Worldwide, breast cancer has now surpassed lung cancer as the most commonly diagnosed cancer worldwide. The estimated 2.3 million new cases indicate that 1 in every 8 cancers diagnosed in 2020 is breast cancer. With approximately 685,000 deaths in 2020, breast cancer is the fifth-leading cause of cancer death worldwide. [3] In the U.S., it is estimated that there will be 290,560 new cases of breast cancer in 2022. [4]

Approximately 70% of all breast cancers are of the HR+, HER2- subtype. [5]

Advertisement #3


Undated analyses
Updated results from the pivotal Phase 3 monarchE trial of adjuvant abemaciclib  in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer shows an absolute improvement in invasive disease-free survival (IDFS) and distance relapse-free survival (DRFS).

These data, presented today as an oral presentation at the San Antonio Breast Cancer Symposium (SABCS), held December 6 – 10, 2022 in San Antonio, Tx., and simultaneously published in The Lancet Oncology, include results for investigational uses in the intent-to-treat (ITT) and Cohort 1 populations.

The updated results from a prespecified analysis reflecting a median follow-up of 3.5 years, with all patients having now discontinued or completed the two-year abemaciclib treatment period.

The absolute increase in invasive disease-free survival (IDFS) and distance relapse-free survival (DRFS) continued to deepen in magnitude at four years, to 6.4% and 5.9%, respectively, reflecting improvements from the two- and three-year rates.

This IDFS and DRFS benefit was seen across all prespecified subgroups, regardless of Ki-67 score. While overall survival (OS) data remain immature at this time, fewer deaths were observed in the abemaciclib-plus-ET arm compared to the ET monotherapy arm (HR=0.929, 95% CI: 0.748, 1.153). There were no new safety findings, and overall results are consistent with the well-established safety profile for abemaciclib.

Stephen Johnston, MD, Ph.D, is the Head of Medical Oncology, Head of the Breast Unit, Professor of Breast Cancer Medicine and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden from 2007 to 2012, and is currently Clinical Director of the Breast, Lung and AOS Clinical Business Unit at The Royal Marsden.

“These results from the monarchE trial provide further evidence of the clinically meaningful benefit that adjuvant abemaciclib adds to standard endocrine therapy in patients with high risk early breast cancer, a population with an urgent need to intensify therapy,” noted Stephen Johnston, M.D., Ph.D., Professor of Breast Cancer Medicine and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust (London, U.K.) and lead investigator for the monarchE trial.

“Moreover, this benefit continues to deepen at four years, well beyond the two-year treatment course with adjuvant Verzenio,” he added.

Study design and outcome
The monarchE trial (N=5,637) included women and men with HR+, HER2-, node-positive early breast cancer with a high risk of disease recurrence. The ITT population included patients enrolled to both Cohort 1 and Cohort 2, with Cohort 1 (N=5,120) representing 91% of all enrolled patients.

Cohort 1 enrolled patients based on high risk clinical pathological factors (≥4 positive axillary lymph nodes [ALN], or 1-3 positive ALN and either Grade 3 disease or tumor size ≥5 cm). Cohort 2 enrolled patients with 1-3 positive ALN and centrally determined Ki-67 score of ≥20% (defined in the study as “Ki-67 high”). Ki-67 is a marker of cellular proliferation. Ki-67 score was also determined centrally in Cohort 1 patients with a suitable sample, but Ki-67 determination was not required for enrollment in this cohort.

At the July 1, 2022 data cutoff, in the ITT population, the risk of developing invasive disease was reduced by 33.6% (HR=0.664, 95% CI: 0.578, 0.762; nominal p<0.0001). The four-year IDFS rate was 85.8% for patients treated with Verzenio plus ET compared to 79.4% for patients treated with ET alone, reflecting an absolute difference of 6.4% (compared to 2.8% at two years).

The majority of the IDFS events were distant metastatic disease. Adjuvant Verzenio also reduced the risk of developing metastatic disease by 34.1% (HR=0.659, 95% CI: 0.567, 0.767; nominal p<0.0001).

The four-year DRFS rate was 88.4% for patients treated with Verzenio plus ET compared to 82.5% for patients treated with ET alone, an absolute difference of 5.9% (compared to 2.5% at two years). Consistent with the findings of previous analyses, a high Ki-67 score correlated with increased risk of recurrence, but IDFS and DRFS results showed a similar benefit regardless of Ki-67 status. The data presented at San Antonio Breast Cancer Symposium also included efficacy outcomes in the U.S. Food and Drug Administration (FDA-) approved population, as well as the Cohort 1 population.

Overall Survival
In the updated analyses, the data for Overall Survival (OS) remained immature. Fewer deaths were observed in the abemaciclib-plus-ET arm (157 [5.6%] of 2,808 patients) compared to the ET monotherapy arm (173 [6.1%] of 2,829 patients) (HR=0.929, 95% CI: 0.748, 1.153; p = 0.50). Fewer deaths due to breast cancer occurred in the Verzenio-plus-ET arm compared to the ET alone arm (117 [4.2%] of 2,791 patients vs. 138 [4.9%] of 2,800 patients). Nearly twice as many patients in the control arm have developed and are living with metastatic disease compared to those receiving Verzenio. Continued follow-up is ongoing until final assessment of OS.

Adverse events
The most frequently observed adverse events (AEs) were diarrhea, neutropenia, and fatigue in the Verzenio arm, and arthralgia, hot flush, and fatigue in the control arm; the most common Grade 3-4 AEs were neutropenia, leucopenia, and diarrhea in the Verzenio arm and arthralgia, neutropenia, and ALT increased in the ET alone arm.

“The continued strengthening of the adjuvant Verzenio benefit seen at four years further underscores the potential importance of these data for women and men with HR+, HER2-, node-positive, high risk early breast cancer,” said David Hyman, M.D., chief medical officer, Loxo@Lilly.

“We are pleased with these results and have submitted an application with the FDA to expand our adjuvant indication in the U.S. based on these data.”

As previously published in the Journal of Clinical Oncology, [6] and subsequently updated in the Annals of Oncology, [7] monarchE met its primary endpoint of a statistically significant improvement in IDFS in the ITT population for patients treated with adjuvant abemaciclib plus ET compared to those treated with ET alone. Consistent with expert guidelines, IDFS was defined as the length of time before breast cancer comes back, any new cancer develops, or death.

Note: a Node-positive breast cancer means that cancer cells from the tumor in the breast have been found in the lymph nodes in the armpit area. Although the breast cancer is removed through surgery, the presence of cancer cells in the lymph nodes signifies that there is a higher chance of the cancer returning and spreading.

Clinical trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) – NCT03155997

Highlights of prescribing information
Abemaciclib (Verzenio®; Eli Lilly and Company) [Prescribing Information]

[1] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0.
[2] Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment–a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012;21:800-809.
[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249
[4]American Cancer Society. Cancer Statistics Center. Online. Last accessed December 4, 2022.
[5] National Cancer Institute, SEER. Cancer Stat Facts: Female Breast Cancer. Online. Last accessed December 4, 2022.
[6] Johnston SRD, Harbeck N, Hegg R, et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE) [published online ahead of print, September 20, 2020]. J Clin Oncol. doi:10.1200/JCO.20.02514.
[7] Harbeck N, Rastogi P, Martin M, et al; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015.

Featured image: Attendees during morning sessions of the 2018 San Antonio Breast cancer Symposium. Photo Courtesy 2018 – 2022 AACR/SABCS. Used with permission.


Advertisement #5